MAGE-3 (111-126)

MAGE-3 (111-126) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, a member of the cancer-testis antigen family. As a defined peptide sequence corresponding to amino acids 111 through 126 of the MAGE-3 protein, it plays a significant role in immunological and cancer research, particularly in the study of antigen presentation and T-cell epitope mapping. The unique sequence of this peptide enables researchers to investigate specific immune responses and molecular interactions relevant to tumor immunology, antigen processing, and the development of peptide-based research tools.

Epitope mapping: In immunological studies, the MAGE-3 (111-126) peptide serves as a valuable tool for mapping T-cell epitopes within the MAGE-3 protein. By utilizing this peptide in assays such as ELISPOT, intracellular cytokine staining, or peptide-MHC tetramer analysis, researchers can identify and characterize the specific T-cell populations that recognize this antigenic segment. This approach facilitates a deeper understanding of the immune response to tumor-associated antigens and supports the rational design of immunological assays.

Antigen processing and presentation studies: The defined sequence of this peptide allows for controlled investigations into the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) molecules. By incorporating the peptide into in vitro or ex vivo antigen presentation systems, scientists can dissect the molecular requirements for peptide loading onto MHC class I or class II molecules, assess the stability of peptide-MHC complexes, and evaluate the efficiency of antigen recognition by T-cell receptors.

Peptide-based assay development: The MAGE-3 (111-126) fragment is frequently employed as a standard or positive control in the development and validation of peptide-based immunoassays. Its well-characterized nature and immunogenic properties make it suitable for optimizing assay sensitivity and specificity, benchmarking experimental protocols, and calibrating detection systems for T-cell activation or cytokine release in response to tumor antigens.

Synthetic peptide library screening: As part of a broader peptide library, MAGE-3 (111-126) can be utilized in high-throughput screening applications to identify immunodominant regions within the MAGE-3 protein or to compare the immunogenicity of different peptide variants. This facilitates the discovery of novel epitopes, the assessment of cross-reactivity with related antigens, and the advancement of peptide-based research in cancer immunology.

Cellular functional studies: The peptide's defined sequence supports its use in functional assays to evaluate T-cell activation, proliferation, and cytotoxicity in response to antigenic stimulation. By pulsing antigen-presenting cells with this peptide, researchers can investigate the downstream effects on immune cell signaling pathways, effector function, and the modulation of immune responses in vitro. These studies provide critical insights into the cellular mechanisms underlying antigen-specific immunity and the potential for targeted immunological interventions in a research context.

1. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs